The findings presented here suggest a novel therapeutic approach to the Olaparib resistance of ovarian cancer and PADI2 as a prognostic marker in advanced ovarian cancer enhances sensitivity of Olaparib to ovarian cancer. The gene discussed is PADI2; the disease is ovarian cancer.